New ETF Book by Larry Connors - Click here to read more
The London company, whose U.S. headquarters are in Wilmington, also announced a 22 percent rise in third-quarter net income, helped by initial sales of its H1N1 flu vaccine.
Expected increases in H1N1 vaccine sales led the company to boost its full-year forecast to a range of $6.20 to $6.40 a share, from $5.70 to $6.
The U.S. Attorney's office in Philadelphia would not comment on its inquiry into AstraZeneca's promotion of its antipsychotic drug Seroquel. The investigation focuses on whether AstraZeneca promoted the drug, which is approved to treat schizophrenia and bipolar disorder, as a treatment for other illnesses.
In a statement, company spokesman Tony Jewell said, "The investigation also related to selected physicians who participated in clinical trials involving Seroquel."
Today, AstraZeneca said it had reached an agreement "in principle" to settle the investigation. The company said it would not comment on whether it would admit to wrongdoing as part of the settlement.
Philadelphia investigators are part of a federal team that has brought cases against many drug companies for marketing products for unapproved uses. Doctors can prescribe a drug for any reason, but a company can promote a product only for uses approved by the U.S. Food and Drug Administration.
In February, the Philadelphia U.S. Attorney's office announced a $1.4 billion settlement with Eli Lilly & Co. over its efforts to market its antipsychotic, Zyprexa, as a treatment for people suffering from dementia and Alzheimer's disease, both unapproved uses.
In today's earnings announcement, AstraZeneca reported net income of $2.12 billion for three months that ended Sept. 30, up from $1.74 billion in the same period a year ago. Revenue rose 5.5 percent to $8.2 billion, supported by strong demand for the company's cholesterol drug Crestor alongside sales of the H1N1 vaccine and reduced generic competition.
Sales of the H1N1 nasal spray vaccine totaled $152 million in the quarter. AstraZeneca's chief financial officer, Simon Lowth, said that the company was on track to deliver the 40 million doses ordered by the U.S. government by early next year.
Investors remain concerned about the company's future pipeline of drugs, especially after AstraZeneca this week pulled its lung cancer drug Zactima from regulatory clearance lists in the United States and European Union following disappointing trial results.
Seroquel sales were up 12 percent at $1.23 billion over the year-ago quarter.
At midafternoon, AstraZeneca's American depositary receipts were trading at $45.74, up 57 cents (1.26 percent), on the New York Stock Exchange.
This article contains information from the Associated Press.
To see more of The Philadelphia Inquirer, or to subscribe to the newspaper, go to http://www.philly.com. Copyright (c) 2009, The Philadelphia Inquirer Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
